Capital Advisors Ltd’s Vaxcyte PCVX Stock Holding History

Capital Advisors Ltd’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$58K	Hold	1,000	–	–	0.01%	490
2026 Q1	$58K	Buy	+1,000	New	+$54.3K	0.01%	469

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Capital Advisors Ltd's PCVX Position: Q2 2026 in Review

Capital Advisors Ltd held its Vaxcyte (PCVX) position steady in Q2 2026 at 1,000 shares worth $58K. The position accounts for 0.01% of the portfolio, ranked #490.

Capital Advisors Ltd first reported a position in PCVX in Q1 2026 and has held it in 2 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Capital Advisors Ltd held 1,000 shares of Vaxcyte worth $58K as of Q2 2026.
Capital Advisors Ltd left its Vaxcyte share count unchanged in Q2 2026.
Vaxcyte made up 0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #490 holding.
Capital Advisors Ltd first reported a position in Vaxcyte in Q1 2026 and has held it in 2 quarters since.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.